Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Flu and pertussis vaccination during pregnancy in Geneva during the COVID-19 pandemic: A multicentric, prospective, survey-based study

M. Lumberras Areta, A. Valiton, A. Diana, M. Morales, J. Wiederrecht-Gasser, S. Jacob, A. Chilin, S. Quarta, C. Jaksic, JR. Vallarta-Robledo, B. Martinez de Tejada

Objective: To determine pertussis and influenza vaccination coverage during pregnancy among women delivering in all the maternities of Geneva (Switzerland), during the COVID-19 pandemic.

Methods: All women delivering in all the maternity centres of the canton of Geneva from 1st November 2020 to 30th November 2020 (beginning of the flu vaccination season) and from 8th March 2021 to 7th April 2021 (end of the flu vaccination season) had their records checked upon admission to the labour ward regarding pertussis and influenza vaccination during pregnancy. Reasons for non-vaccination were recorded. Univariate and multivariate analyses were done to identify predictors of vaccine uptake.

Results: 951 women delivered in Geneva during the two study periods, of which 950 were included in the study. 86.2% were vaccinated against pertussis, with no significant difference between the study periods (87.5% vs 85% at the beginning and end of the flu vaccination season respectively). 49.8% were vaccinated against influenza, with no significant difference between the study periods (48.8% vs 50.7% beginning and end of the flu vaccination season respectively). The influenza vaccine was 5 times more likely not to be proposed (8.9% vs. 1.7%) and 3 times more likely to be refused (26.6% vs. 8%) than the pertussis vaccine. Main reason for refusal was a lack of maternal desire for both vaccines, but not vaccine fear. Maternal parity > 1 was significantly associated with pertussis vaccine uptake at univariate analysis. Women were significantly more likely to accept the influenza vaccine if they had a university degree or if they did not deliver in a midwife-only run delivery unit in both univariate and multivariate analysis.

Conclusions: In Geneva, most gynaecologists offer pertussis immunization during antenatal care and uptake is high, but more efforts must be done to increase influenza vaccination coverage. Education level impacts maternal flu vaccination uptake, but other social disparities did not.

1. Introduction

In Switzerland, the Federal Office of Public Health (FOPH) recommends immunization during pregnancy against pertussis and influenza. Pertussis, caused by *Bordatella pertussis*, is transmitted by airborne droplets and causes recurrent outbreaks [1,2]. Although pertussis can occur at any age, it is more frequent and severe in infants < 6 months [3]. The rationale of antenatal pertussis immunization is to boost maternal antibody levels in order to maximise the amount transferred to the foetus, thus protecting the newborn by passive immunity during the early vulnerable months, until it generates its own active immunity via childhood vaccination. On the other hand, antenatal influenza immunization is recommended to protect both the mother and the infant, as the virus causing seasonal flu causes more severe disease in pregnant women [4,5], and increases the rate of miscarriage, intrauterine growth restriction (IUGR), prematurity and infant mortality [6]. Antenatal immunization against influenza and pertussis, recommended in Switzerland since 2010 and 2013 respectively, is...
both safe [7–14] and effective. Vaccine effectiveness (VE) for antenatal pertussis immunization is 91–95% [15,16], with maximum neonatal protection obtained when the vaccine is done during 2nd versus 3rd trimester [17,18]. This strategy is more effective than the “cocooning strategy”, which is a complimentary strategy for close family members, but on its own only reduces the rate of neonatal pertussis by 6% [19]. VE for influenza antenatal immunization varies between 50 and 80% depending on the studies [20,21].

The current national recommendation is to vaccinate pregnant women against pertussis as of 13 gestational weeks (ideally between 13 and 26 gestational weeks), repeating vaccination at each pregnancy as maternal antibody levels decline significantly 1-year post-immunization. Antenatal influenza immunization is recommended during the entire epidemic season (from October until April) independent of gestational age [22].

Although pertussis and influenza antenatal immunization has been recommended in Switzerland for several years, there is no official data concerning vaccination coverage. Our study was designed at a cantonal level, including all maternity units of Geneva, and its primary objective was to determine the rate of antenatal vaccination coverage. Secondary objectives were to identify reasons for vaccine refusal and maternal predictors associated with vaccine uptake.

2. Methods

This is a multicentric, prospective, survey-based study including women delivering in all five maternity in the canton of Geneva, Switzerland (Hôpitaux Universitaires de Genève [HUG], Clinique des Grangettes [CG], Clinique Générale Beaulieu [CGB], Hôpital de la Tour [HT], Maison de naissance la Roseraie [MNR]) during two periods during the COVID-19 pandemic: from 1st November 2020 to 30th November 2020 (beginning of the flu vaccination season) and from 8th March 2021 to 7th April 2021 (end of flu vaccination season). Inclusion criteria were women ≥18 years and live birth after 24 gestational weeks (GW). Women with pregnancy termination or miscarriage before 24 GW or unfollowed pregnancies were excluded. All data were recorded anonymously. The National Ethics Committee approved the research protocol (Swiss Ethics Committees on research involving humans).

Upon admission to the labor ward, all patients’ records were checked by midwives and/or doctors for vaccination during pregnancy (pertussis and influenza). We recorded: implementation (yes/no); timing of vaccination; reason for non implementation (refusal; not proposed; reason unknown); reasons for refusal (fear of vaccination; not interested; other). We also gathered: maternal age, gestational age at delivery, ethnicity (Caucasian, African, Hispanic, other), gestity, parity, highest level of education (obligatory secondary school, high school [leading to Swiss baccalaureate or equivalent], university degree), residential postal code (France and Switzerland) and type of delivering maternity setting (university hospital, private clinic, midwife-led setting).

Statistical analyses were conducted using R (v.4.1.0). Continuous variables are reported as mean and standard deviation and categorical variables are reported as count and proportion. For women to whom the vaccine was proposed, univariate and multivariate logistic regressions were done to investigate the effect of maternal age, ethnicity, gestity, parity, county of residence (France vs Switzerland), education level and type of delivery maternity unit on vaccine uptake.

We also carried out a subgroup analysis for patients living in Geneva, for which income levels was deduced from their postal code, as per the data published by Vallarta-Robledo et al. [23], who obtained annual median neighborhood household income (only reported for married couples) between 2005 and 2016 from the Cantonal Office of Statistics (OCSTAT). Categories of these revenues (100’000-150’000 CHF/year, 150’000-250’000 CHF/year, ≥250’000 CHF/year) were compared between patients who accepted the vaccine and those who refused, using a chi-square test.

Comparisons between the 2 studies periods were also done. A p-value < 0.05 was considered significant.

3. Results

A total of 951 women delivered in Geneva during the two study periods. 450 delivered between 1st and 30th November 2020 (HUG: 322; other maternity units: 128 [CG: 56, CGB: 40, HT, 27, MNR: 5]; 501 delivered between 8th March 2021 and 7th April 2021 (HUG: 312; other maternity units: 189 [CG: 61, CGB: 73, HT, 47, MNR: 8]. Data from 1 patient who delivered in CG in November was excluded due to error in data collection. The characteristics of the 950 eligible participants are shown in Table 1. The mean (±standard deviation) maternal age and gestational weeks (GW) at delivery were 32.8 years (±5.1) and 39.3 GW (±1.7). Characteristics of women did not significantly differ between the two study periods, with the exception of the type of delivery unit, with significantly more patients delivering in private clinics in the second study period with respect to the first.

Antenatal vaccination coverage was higher for pertussis (86.2%) than for influenza (49.8%), with no significant differences in coverage between the two study periods. The influenza vaccine was more often not proposed (8.9% vs 1.7%), and more likely to be refused when proposed (26.6% vs 8.0%), than that against pertussis. In both cases, the main reason for vaccine refusal was reported to be a lack of interest from the mother, and not vaccine fear (Table 2). When carried out, pertussis immunization was more often done in the 3rd trimester of pregnancy (63.8%) than in the 2nd one (36.2%). Pertussis vaccine status was missing in one of the questionnaires.

Univariate logistic regression showed that the only independent variable significantly associated with pertussis vaccine uptake was maternal parity. Due to the low proportion of patients refusing this vaccine, no further analysis was carried out (Table 3).

Regarding the influenza vaccine, the level of maternal education and type of delivery setting were significant variables in both univariate and multivariate analysis, with women being significantly more likely to be vaccinated if they had a university degree and if they did not deliver in a midwife-lead delivery setting (Tables 4 and 5). There was no significant difference in influenza vaccine uptake based on income in the subgroup analysis done on patients living in Geneva (Table 4). The income level in patients living in Geneva was not included in the multivariate analysis to avoid multi-collinearity problems with other factors already included in the model (i.e. country of residence).

4. Discussion

To our knowledge, this is the first study in Switzerland to assess antenatal pertussis and influenza vaccination coverage during pregnancy, as well as factors influencing vaccine uptake. The study included all pregnant women delivering in all the maternity settings of the whole canton of Geneva.

We have seen that whereas the majority of women delivering in Geneva received pertussis immunization during pregnancy (86.2%), less than half received the influenza vaccine (49.8%). This disparity was not due to the seasonal nature of flu (one could think that patients delivering in November had little time to receive the vaccine), as no statistical difference was observed in rates of influenza vaccine uptake between the two study periods.
Higher acceptance of pertussis versus influenza vaccine has also been found in studies in England (72.6% vs 44.8% in 2017)[24], Australia (71% vs 61% in 2015)[25] and the USA[26]. One of the reasons for this may be that antenatal pertussis vaccination benefits the newborn, whereas the flu vaccine is often portrayed as protecting the mother[27,28]. Since mothers value protecting their newborn more highly than protecting themselves [29], framing influenza vaccine information towards neonatal benefit may help

### Table 1
Characteristics of women.

|                  | Entire study N = 950 | November period N = 449, 47.3% | March-April period N = 501, 52.7% | p-value (chi²) |
|------------------|----------------------|--------------------------------|-----------------------------------|----------------|
| **Maternal age (years)** |                      |                                |                                   |                |
| 18–24            | 44 (4.7)             | 16 (3.6)                       | 28 (5.7)                          | 0.316          |
| 25–34            | 544 (57.7)           | 262 (58.5)                     | 282 (57.0)                        |                |
| ≥35              | 355 (37.6)           | 170 (37.0)                     | 185 (37.4)                        |                |
| Missing values   | 7 (0.7)              | 1                              | 6                                 |                |
| **Ethnicity**    |                      |                                |                                   | 0.865          |
| Caucasian        | 682 (72.1)           | 323 (72.4)                     | 359 (71.8)                        |                |
| African          | 114 (12.1)           | 56 (12.6)                      | 58 (11.6)                         |                |
| Hispanic         | 89 (9.4)             | 41 (9.2)                       | 48 (9.6)                          |                |
| Other            | 61 (6.4)             | 26 (5.8)                       | 35 (7.0)                          |                |
| Missing values   | 4 (0.4)              | 3                              | 1                                 |                |
| **Gestility**    |                      |                                |                                   | 0.536          |
| 1                | 316 (33.3)           | 157 (35.0)                     | 159 (31.7)                        |                |
| 2                | 315 (33.2)           | 141 (31.4)                     | 174 (34.7)                        |                |
| 3                | 166 (17.5)           | 75 (16.7)                      | 91 (18.2)                         |                |
| ≥4               | 153 (16.1)           | 76 (16.9)                      | 77 (15.4)                         |                |
| **Parity**       |                      |                                |                                   | 0.984          |
| 0                | 378 (39.8)           | 178 (39.6)                     | 200 (39.9)                        |                |
| ≥1               | 572 (60.2)           | 271 (60.4)                     | 301 (60.1)                        |                |
| **Highest level of education** |                |                                |                                   | 0.086          |
| University degree| 378 (41.6)           | 173 (41.1)                     | 205 (42.1)                        |                |
| High school      | 268 (29.5)           | 138 (32.8)                     | 130 (26.7)                        |                |
| Secondary school | 262 (28.9)           | 110 (26.1)                     | 152 (31.2)                        |                |
| Missing values   | 42 (4.4)             | 28                             | 14                                |                |
| **Country of residence** |                      |                                |                                   | 0.606          |
| Switzerland      | 894 (94.7)           | 422 (94.2)                     | 472 (95.2)                        |                |
| France           | 50 (5.3)             | 26 (5.8)                       | 24 (4.8)                          |                |
| Missing values   | 6 (0.6)              | 1                              | 5                                 |                |
| **Delivery unit**|                      |                                |                                   | 0.009          |
| University hospital | 634 (66.7)         | 322 (71.7)                     | 312 (62.3)                        |                |
| Private clinic   | 303 (31.9)           | 122 (27.2)                     | 181 (36.1)                        |                |
| Midwife only     | 13 (1.4)             | 5 (1.1)                        | 8 (1.6)                           |                |

N = number.

### Table 2
Vaccination coverage and reason for non vaccination.

| Vaccine      | Vaccinated N (%) | Non vaccinated N (%) | N total | p-value (chi²) |
|--------------|------------------|----------------------|---------|----------------|
| Pertussis    |                  |                      |         |                |
| November     | 818 (86.2)       | 131 (13.8)           | 949     | 0.314          |
| March-April  | 392 (87.5)       | 56 (12.5)            | 448     |                |
| Influenza    | 426 (85.0)       | 75 (15.0)            | 401     |                |
| November     | 473 (49.8)       | 477 (50.2)           | 950     | 0.598          |
| March-April  | 219 (48.8)       | 230 (51.2)           | 450     |                |
| Reason for non vaccination |                  |                      |         |                |
| Pertussis    |                  |                      |         |                |
| Refusal      | 76 (8.0)         | 3 (3.9)              | 79      |                |
| Not interested | 37 (8.7)        | 10 (2.2)             | 47      |                |
| Other        | 16 (1.7)         | 36 (8.1)             | 52      |                |
| Unknown reason | 169 (4.3)       | 153 (30.5)           | 179     |                |
| Influenza    |                  |                      |         |                |
| Refusal      | 253 (26.6)       | 10 (4.0)             | 263     |                |
| Not interested | 153 (60.5)      | 90 (35.6)            | 243     |                |
| Other        | 85 (8.9)         | 90 (35.6)            | 175     |                |
| Unknown reason | 139 (14.6)      | 70 (28.4)            | 209     |                |

N = number.
improve its uptake [30]. Other barriers to influenza vaccination is lack of knowledge about the severity of influenza disease [31], concerns regarding the safety for the foetus, its lower effectiveness versus pertussis vaccine [32] and opinions of family and friends [33]. Another factor that may explain the success of pertussis vaccination in Geneva, was the tragic death of a young infant in the near canton of Vaud in 2015 from whooping cough, whose mother was not offered the vaccine during her pregnancy. This case was well publicized by media, informing the public of the severity of the disease and reminding them that it remains a current problem.

This study was carried out during the COVID-19 pandemic, where social distancing and hygiene measures greatly reduced the seasonal flu epidemic in Switzerland [34]. Since these exceptional circumstances could have impacted vaccine uptake, we carried out an analysis to determine antenatal vaccine uptake before the pandemic. In 2019, the rates of antenatal vaccination in the University Hospitals of Geneva were 84% for pertussis and 37% for flu. Therefore during the Covid-19 pandemic, the rates of antenatal immunization were similar for pertussis but much higher for flu. The latter might indicate that pregnant women and care-givers were more aware about the potential higher risk of pregnancy complications due to two on-going respiratory viral diseases which might have increased both proposal and vaccine uptake. Since the FOPH now also recommends the COVID-19 vaccine in all pregnant women since April 2021 [35], it will be interesting to see if these new guidelines impact the uptake of the other vaccines during

Table 3
| Vaccinated (N = 818, 91.5%) | Non vaccinated (N = 76, 8.5%) | p-value (chi²) |
|-----------------------------|-----------------------------|---------------|
| **Age (years)** | | | 0.051<sup>1</sup> |
| 18–24 | 33 (4.1) | 7 (9.2) | |
| 25–34 | 478 (58.4) | 36 (47.4) | |
| ≥35 | 301 (36.7) | 32 (42.1) | |
| Missing values | 6 (0.7) | 1 (1.3) | |
| **Ethnicity** | | | 0.342<sup>1</sup> |
| Caucasian | 584 (71.4) | 58 (76.3) | |
| African | 97 (11.9) | 11 (14.5) | |
| Hispanic | 81 (9.9) | 3 (3.9) | |
| Other | 52 (6.4) | 4 (5.3) | |
| Missing values | 4 (0.5) | 0 | |
| **University degree** | | | 0.054 |
| Yes | 338 (41.3) | 23 (30.3) | |
| No | 443 (54.2) | 51 (67.1) | |
| Missing values | 37 (4.5) | 2 (2.6) | |
| **Country of residence** | | | 0.597<sup>1</sup> |
| Switzerland | 769 (94.0) | 70 (92.1) | |
| France | 44 (5.4) | 5 (6.6) | |
| Missing values | 5 (0.6) | 1 | 1.3 |
| **Delivery setting** | | | 0.169<sup>1</sup> |
| University hospital | 546 (66.7) | 54 (71.1) | |
| Private clinic | 264 (32.3) | 20 (26.3) | |
| Midwife only | 8 (1.0) | 2 (2.6) | |
| **Subgroup analysis** | | | 0.383<sup>1</sup> |
| Income levels (CHF/year) | | | |
| 0–100’000 | 484 (67.9) | 38 (63.3) | |
| 100’000–150’000 | 178 (25.0) | 15 (25.0) | |
| ≥150’000 | 51 (7.2) | 7 (11.7) | |

N = number, 1 Fisher’s exact.

Table 4
| Vaccinated (N = 473, 65.2%) | Non vaccinated (N = 253, 34.8%) | p-value (chi²) |
|-----------------------------|-----------------------------|---------------|
| **Age (years)** | | | 0.522<sup>1</sup> |
| 18–24 | 21 (4.5) | 15 (5.9) | |
| 25–34 | 271 (57.8) | 151 (59.7) | |
| ≥35 | 177 (37.7) | 87 (34.4) | |
| Missing values | 4 | 0 | |
| **Ethnicity** | | | 0.237 |
| Caucasian | 333 (70.4) | 189 (75.3) | |
| African | 56 (11.8) | 32 (12.7) | |
| Hispanic | 50 (10.6) | 17 (6.8) | |
| Other | 34 (7.2) | 13 (5.2) | |
| Missing values | 0 | 2 | |
| **University degree** | | | 0.009 |
| Yes | 212 (46.8) | 88 (36.2) | |
| No | 241 (53.2) | 155 (63.8) | |
| Missing values | 20 | 10 | |
| **Country of residence** | | | 0.282 |
| Switzerland | 447 (95.1) | 234 (92.9) | |
| France | 23 (4.9) | 18 (7.1) | |
| Missing values | 3 | 1 | |
| **Delivery unit** | | | 0.006<sup>1</sup> |
| University hospital | 310 (65.5) | 165 (65.2) | |
| Private clinic | 161 (34.0) | 79 (31.2) | |
| Midwife only | 2 (0.4) | 9 (3.6) | |
| **Subgroup analysis** | | | 0.801 |
| Income levels (CHF/year) | | | |
| 100’000–150’000 | 274 (67.0) | 149 (69.3) | |
| 150’000–200’000 | 103 (25.2) | 49 (22.8) | |
| ≥200’000 | 32 (7.8) | 17 (7.9) | |

N = number, 1 Fisher’s exact.

Table 5

| Variables affecting influenza vaccination based on multivariate analysis. | Odds ratio | 95% CI |
|-----------------------------|-------------|-------|
| **Age - continuous (years)** | 1.009 | 0.974 – 1.045 |
| **Ethnicity** | | |
| Caucasian | reference | |
| African | 0.941 | 0.572–1.568 |
| Hispanic | 2.076 | 1.121–4.082 |
| Other | 1.432 | 0.730–2.986 |
| **Gestation** | | |
| 1 | reference | |
| 2 | 0.938 | 0.540 – 1.648 |
| 3 | 0.967 | 0.511 – 1.849 |
| ≥4 | 1.952 | 0.970 – 4.004 |
| **University degree** | | |
| No | reference | |
| Yes | 1.394 | 0.833 – 2.367 |
| **Country of residence** | | |
| France | reference | |
| Switzerland | 1.495 | 0.745–2.961 |
| **Delivery setting** | | |
| University hospital | reference | |
| Private clinic | 0.528 | 0.640–1.348 |
| Midwife only | 0.108 | 0.016–0.437 |

CI = confidence interval.
An odds ratio > 1 represents a higher chance of being vaccinated.
antenatal care, as some patients may find having to receive 3 different types of vaccine during pregnancy a little excessive.

Safety concerns have often been cited as a major reason for vaccine rejection [26]. However, our study found that maternal lack of interest was the main cause for vaccine refusal for both vaccines. Unfortunately, specific details regarding the reasons for this lack of interest were not recorded, but 32% of the women that had mentioned a lack of interest for pertussis antenatal immunization cited as a reason having already been immunized in the past. Only a few women that chose “other” as a reason for vaccine rejection cited plans to do so in the post-partum. Although vaccines are systematically offered in the post partum at the University Hospitals in Geneva, no data was collected regarding catch-up immunization after birth, since the questionnaire was filled out in the labor suite and post partum catch-up immunization was not the purpose of the study. In order to protect pregnant woman against flu and the newborn against flu and pertussis, the vaccines should be given during the pregnancy.

Our logistic regression model showed that the maternal education was a significant predictor of influenza vaccine uptake during pregnancy. Higher levels of maternal education have already been associated with vaccine uptake during pregnancy in previous studies [33,36], underlining the importance of providing adapted information to patients, which should begin early in antenatal care to give them enough time to reflect and take an informed decision. The other factor that significantly reduced influenza vaccine uptake in univariate and multivariate analysis was delivering in a midwife-lead setting. Recommendations from healthcare professionals play a key role in encouraging vaccination during pregnancy [37], with women often valuing the recommendations and convictions of midwives over that of other health professionals [38]. However, a Canadian survey found that recommendations for influenza vaccination during pregnancy vary among healthcare members, with midwives (38%) being less likely than physicians (80%) to recommend the influenza vaccine to their patients [39]. Since the information often given to patients on maternal vaccination is often affected by personal perceptions, it is essential to educate all healthcare professionals on current guidelines, especially midwives, who have reported little undergraduate training on maternal vaccination [40]. Maternal age, parity, ethnicity and deprivation level have also been associated with vaccine coverage in other studies [41–43], but were not identified in our study.

Antenatal care providers must do an additional effort to keep in line with current guidelines. Although pertussis acceptance was high, almost two-thirds of women received the vaccine during the third trimester, even though current recommendations favour transfer [17] and protection of premature neonates [44]. In addition, 10% of women said they had not been proposed the influenza vaccine. As previously mentioned, this may be due to personal perceptions of healthcare providers, but it may also result from the seasonal nature of this vaccine, with caregivers being more likely to forget it, underlining the importance of integrating it into the standard of antenatal care.

The strengths of this study are that it is the first study in Switzerland regarding antenatal vaccine coverage, that it is multicentric and includes a large number of participants. Weaknesses are that data was obtained only in Geneva, and vaccination coverage probably varies greatly within the country. Also, factors that are known to affect vaccine uptake such as history of previous vaccination, number of prenatal care visits, perceived risk of disease, or previous chronic conditions [45,46] were not investigated further and are not incorporated into our analysis.

We did not record data on the type of prenatal care provider (midwife, private doctor, university hospital), thus omitting practice specific recommendations that may influence vaccine uptake, and which are therefore not accounted for in our multivariate analysis. However, the reason why this was omitted is because in Geneva, 80% of the women delivering in the university hospital receive prenatal care in private practices anyways, making the follow-up quite similar. We decided to focus on comparing type of delivery unit, as delivering in the university hospital versus delivering in private hospital/midwife-run unit, added the possibility of further proposing the vaccines at the end of pregnancy (women receiving prenatal care in private practice who plan to deliver in the university hospital are referred to the latter at 36 gestational weeks), as the university hospital has the policy to inform and propose both vaccines among un-vaccinated women regardless if they have been proposed by the treating obstetrician.

Further studies should focus on identifying more precisely the reasons behind the lack of interest in vaccines leading to refusal and the association between type of care provider and vaccine uptake in order to help direct efforts to improve immunization coverage.

5. Conclusion

In Geneva, most women receive pertussis vaccination during antenatal care. More efforts have to be done to increase rates of influenza immunization with strategies directed to better informing both patients and healthcare professionals. Ethnicity and deprivation level have no impact in vaccination uptake in Geneva.

6. Disclosure statement

The study was funded with an unrestricted grant of the “Direction Generale de la Santé” of Geneva.

BMT has participated in advisory boards of GSK, Effik, Pierre-Favre and Norgine Pharma.

Author contributions

All authors attest they meet the ICMJE criteria for authorship. Conceptualization, MLA, BMT; methodology and data collection, MLA, BMT, AC, AV, MAM, JWG, SJ, AD, SQ; data analysis, CJ, MLA, JRVR; writing - original draft, MLA, BMT; writing - review and editing, AC, CJ, JRVR. All authors have read and agreed to the published version of the manuscript.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We greatly appreciate the assistance of Ms Nathalie Soumet Trinquart in data management and of the Research platform of the Department of Pediatrics, Gynecology and Obstetrics.

References

[1] CDC. Pertussis outbreak trends. [cited 2017 25 April]; Available from: www.cdc.gov/pertussis/outbreaks/trends.html
[2] PHE. Public Health England (PHE) enhanced pertussis surveillance. [cited 2017 25 April]; Available from: http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/hpr/archives/2013/news0513.htm - access.
[3] Forsyth K, Plotkin S, Tan T, Wirsing von König CH. Strategies to decrease pertussis transmission to infants. Pediatrics 2015;135(6):e1475–82.
[4] Dodd LS, Neil SA, Felli DB, Allen VM, Coombs A, Scott J, et al. Impact of influenza exposure on rates of hospital admissions and physician visits...
because of respiratory illness among pregnant women. CMAJ 2007;176(4):463–8.

[3] Schanzer DL, Langle PY, Tam TW. Influenza-attributed hospitalization rates among pregnant women in Canada 1994–2000. J Obstet Gynaecol Can 2007;29(8):622–9.

[4] Bhat N, Wright JC, Broder KR, Murray EL, Greenberg ME, Glover MJ, et al. Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med 2005;353(24):2559–67.

[5] Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014;311(17):1760.

[6] Zbyteyeva YA, Moro PL, Tepper NK, Rasmussen SA, Barash FE, Revzina NV, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol 2012;207(1):e1–7.

[7] Donegan K, King B, Bryan P. Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ 2014;349:g3219.

[8] Khbendar A, Khzam-Benitez G, Lipkinds K, Klein NP, Cheetham TC, Nalwala A, et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA 2014;312(18):1897.

[9] Shakib JH, Korgenski K, Sheng X, Varner MW, Pavia AT, Byington CL. Acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes. J Pediatr 2013;163(2):1422–26.

[10] Trotta, F., et al., Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study. BMJ 2014;348. p. g3861.

[11] Nordin JD, Khbendar A, Khzam-Benitez G, Lipkinds K, Vellozzi C, Desfèo F. Maternal influenza vaccine and risks for preterm or small for gestational age birth. J Pediatr 2014;164(3):1051–1057.

[12] Chambers CD, Johnson D, Xu R, Luo Y, Louik C, Mitchell AA, et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine 2013;31(44):5026–32.

[13] Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Fry NK, Ramsay M, Miller E, et al. Predictors of antenatal vaccine uptake: A national study. Lancet 2014;384(9953):1521–8.

[14] Amirthalingam G, Campbell H, Ribeiro S, Fry NK, Ramsay M, Miller E, et al. Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction. Clin Infect Dis 2016;63(suppl 4):S236–43.

[15] Eberhardt CS, Blanchard-Rohner G, Lemaître B, Bouchard M, Combescure C, Othenin-Girard V, et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis 2016;62(7):829–36.

[16] Eberhardt CS, B-RG, Lemaître B, Combescure C, Othenin-Girard V, Chlin A, Petre J, Martinez de Tejada B, Siegrist CA, Pertussis antibody transfer to preterm neonates after second - versus third- trimester maternal immunization. Clin Infect Diseases, 2017;64(8):1129–32.

[17] Campbell PT, McVernon J, Geard N. Determining the best strategies for maternal targeted pertussis vaccination using an individual-based model. Am J Epidemiol 2017;186(1):109–17.

[18] Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014;371(10):918–31.

[19] Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359(15):1555–64.

[20] Avis d’expert n 55: Vaccination contre la grippe saisonnière et la coqueluche pendant la grossesse. 2021 28.05.2021; Available from: https://www.sggg.ch/fileadmin/user_upload/55_Impfen_in_der_Schwangerschaft_FR.pdf.

[21] Vallarta-Robledo JR et al. Spatial clusters of daily tobacco consumption before and after a smoke-free policy implementation. Health Place 2021;70:102616.

[22] Vishram B, Leatly L, Jan Van Hoek A, Silverton L, Donovan H, Adams C, et al. Vaccination in pregnancy: attitudes of nurses, midwives and health visitors in England. Hum Vaccin Immunother 2018;14(1):179–88.

[23] Mak DB, Regan AK, Vo DT, Effier PV. Antenatal influenza and pertussis vaccination in Western Australia: a cross-sectional survey of vaccine uptake and influencing factors. BMC Pregnancy Childbirth 2018;18(1).

[24] Strasser ER, Power M, Schulkin J, Stark LM, Mackeen AD, Murtough KL, et al. Patient attitudes toward influenza and tetanus, diphtheria and acellular pertussis vaccination in pregnancy. Vaccine 2018;36(30):4548–54.

[25] Korb J, Aprili F, Varela MA, Costello PM, Laia M, Andres R, Stockwell MS. Exploring pregnant women’s views on influenza vaccination and educational text messages. Prev Med 2011;52(1):75–7.

[26] Wiley KE, Cooper SC, Wood N, Leask J. Understanding pregnant women’s attitudes and behavior toward influenza and pertussis vaccination. Qual Health Res 2015;25(3):360–70.

[27] Maher L, Hope K, Torvoldsen S, Lawrence G, Dawson A, Wiley K, et al. Influenza vaccination during pregnancy: coverage rates and influencing factors in two urban districts in Sydney. Vaccine 2013;31(47):5567–64.

[28] Marsh HA, Malik F, Shapiro E, Omer SB, Frew PM. Message framing strategies to increase influenza immunization uptake among pregnant African American women. Matern Child Health J 2014;18(7):1639–47.

[29] D’Alessandro A, Napolitano F, D’Ambrosio A, Angelillo IF. Vaccination knowledge and acceptability among pregnant women in Italy. Hum Vaccin Immunother 2018;14(7):1573–9.

[30] Wilson BJ, Paterson P, Jarrett C, Larson HJ. Understanding factors influencing vaccination acceptance during pregnancy globally: a literature review. Vaccine 2015;33(34):4824–9.

[31] Maertens K, Baereckman T, Top G, Van Damme P, Leuridan E. Maternal pertussis and influenza immunization coverage and attitude of health care workers towards these recommendations in Flanders, Belgium. Vaccine 2016;34(47):5785–91.

[32] Office fédéral de la santé publique. 2021; Available from: https://www.bag.admin.ch/bag/it/krankenhaus/ausbrueche-epidemien/pertussis-antikuerne-ausbrueche-epidemien/saisonale-grippe--lagebericht-schweiz.html -1189947795.

[33] Société Suisse de Gynécologie et d’Obstétrique: Vaccination contre le COVID-19 pendant la grossesse. 2021 28.05.2021; Available from: https://www.ssgg.ch/fileadmin/user_upload/Dokumente/I_Ueber_uns/Prescription_Infocentenamt_Vaccin_A_28.05.2021_Begleitschreiben.pdf.

[34] Leenen J, Roelants M, Devlieger R, Vandemeuleen C. Influenza and pertussis vaccination coverage in pregnant women. Vaccine 2015;33(18):2125–31.

[35] Paaissance M, Sindos M, Theodora M, Antsaklis P, Pergialiotis V, Loutradis D, et al. Maternal Immunization uncovered: a cross-sectional study investigating factors influencing women’s choices in Flanders, Belgium. Vaccine 2016;34(34):34.

[36] Gauld N, Martin S, Sinclair O, Petousis-Harris H, Dumble F, Grant CC. Influences on pregnant women’s and health care professionals’ behaviour regarding maternal vaccinations: a qualitative interview study. Vaccines 2022;10(1):76.

[37] Dubé E, Cagnon D, Kaminsky K, Green CR, Ouakki M, Bettinger JA, et al. Vaccination against influenza in a pregnancy: a survey of Canadian maternity care providers. J Obstet Gynaecol Can 2019;41(4):479–88.

[38] Frawley JE, McKenzie K, Sinclair L, Cummings A, Wardle J, H Midwifery knowledge, attitudes and confidence in discussing maternal and childhood immunisation with parents: a national study. Vaccine 2020;38(2):366–71.

[39] Wilcox CR, Calvert A, Metz J, Böllheim K, MacLeod R, Beaton K, et al. Determinants of influenza and pertussis vaccination uptake in pregnancy: a multicenter questionnaire study of pregnant women and healthcare professionals. Pediatr Infect Dis J 2019;38(6):625–30.

[40] Carlisle N, Seed PT, Gillman L. Can common characteristics be identified as predictors for seasonal influenza vaccine uptake in pregnancy? A retrospective cohort study from a South London Hospital. Midwifery 2019;72:67–73.

[41] Byrne L, Ward C, White JM, Amirthalingam G, Edelstein M. Predictors of coverage of the national maternal pertussis and infant rotavirus vaccination programmes in England. Epidemiol Infect 2018;146(2):197–206.

[42] Eberhardt CS, et al., Pertussis antibody transfer to preterm neonates after second- versus third-trimester maternal immunization. Clin Infect Dis, 2017. 64(8):1129–1132.